New Anticancer Agent With Minimal Side Effects Has Unique Mechanism of Action

Publication
Article
OncologyONCOLOGY Vol 14 No 2
Volume 14
Issue 2

An ongoing phase I clinical trial shows that a new anticancer agent, CCI-779, is well-tolerated and may have antitumor activity. CCI-779 is a derivative of rapamycin, an immunosuppressive agent. Results of the study were presented at the

An ongoing phase I clinical trial shows that a new anticancer agent, CCI-779, is well-tolerated and may have antitumor activity. CCI-779 is a derivative of rapamycin, an immunosuppressive agent. Results of the study were presented at the International Conference on Molecular Cancer Therapeutics sponsored by the American Association of Cancer Research (AACR), National Cancer Institute (NCI), and European Organization for Research and Treatment of Cancer (EORTC). Jerome Alexander, a physician-in-training and researcher working with senior investigator, Eric Raymond, MD, made the presentation.

“By interfering with key proteins that regulate cell growth, CCI-779 may stop the progression of tumors. This is a unique mechanism of action for an anticancer agent,” said Dr. Raymond, associate professor of oncology at the Institut Gustave Roussy in Villejuif, France. “If these preliminary results are confirmed in future observations, this may represent a new and safer treatment for cancer patients.”

Study Data

For this ongoing phase I study, 12 patients received CCI-779. Three patients with renal cell cancer experienced tumor regression after other treatments had failed. At the doses used so far, the main adverse effects of CCI-779 have been mild skin reactions and inflammation of the mucous membranes, which occurred at all dose levels studied but did not increase in intensity with higher doses or longer duration of treatment.

The new agent appears to block the effect of mTOR, an enzyme that has an important role in regulating the synthesis of proteins that control cell division. Therefore, CCI-779 may stop the production of proteins essential for cancer cell proliferation and possibly survival of cancer cells. According to the researchers, ongoing studies are evaluating other dose levels and a longer treatment duration to confirm the safety and efficacy of CCI-779 before advancing to phase II studies to confirm efficacy in several types of cancer.

Axel Hanauske, MD, PhD, from the Oncology Institute in Munich, Germany, and the sponsor, Wyeth-Ayerst Research in Radnor, Pennsylvania/Genetics Institute in Munich, Germany, are collaborating on the study.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content